Edessa
Clean three-rung tables one click in, behind a homepage whose three cards all quote six-month rungs and whose cheapest belongs to a different drug.
- Semaglutide
- $179/mo month-to-month injectable ($135 only on a 6-month prepay)
- Tirzepatide
- $239/mo month-to-month ($209 only on a 6-month prepay)
- Coverage
- Not publicly listed
- Brand-name
- Compounded only
Weigh Edessa against the full graded field on the best semaglutide providers scorecard, or line it up against its closest alternatives. Because Edessa dispenses compounded medication, it’s worth understanding whether compounded semaglutide is legit and safe.
Factor breakdown
Each of the six graded dimensions. See the methodology.
Strengths
- Each product page carries a plain three-rung table, so the commitment behind every figure is visible
- "Same price, every dose" is printed on each product page
- Names its operating entity and a full street address in Las Vegas, Nevada
- All-inclusive: provider consultation, medication, free expedited shipping, ongoing check-ins and 24/7 clinical support, and HSA and FSA eligible
- An oral tablet sits beside the two injections
Where it loses points
- The homepage leads with "Start for just $135", a six-month prepay on the semaglutide injection; month-to-month tirzepatide is $239
- All three homepage cards quote the six-month rung, so the real monthly rates appear only after a click
- Its Terms give two corporate forms for the same company in one clause — "Edessa Group, LLC, a Nevada corporation"
- "Join 100,000+ successful GLP-1 patients" carries no source, and the money-back guarantee's terms are on no marketing page
- No lab or monitoring protocol is published
Bottom line — Grade C
Best for: A six-month committer, or anyone willing to click past the homepage to the table carrying the real monthly rate.
Ranked #115 of 544 on this scorecard. See our top-scoring pick, CoreAge Rx (#1), for comparison.
Closest here
The rankings grading nearest Edessa — the realistic shortlist.
Heally is a US telehealth platform connecting patients with licensed providers for GLP-1 weight loss prescriptions; care is by HLY Medical Group PA.
Layla is a US telehealth weight-loss program built around semaglutide, offering compounded semaglutide as injections and as oral dropper drops, plus compounded tirzepatide and a brand-inclusive GLP-1 program covering Wegovy, Ozempic, Zepbound, and Mounjaro.
DrBrainRx is a neurologist-founded telehealth clinic led by Dr. Sara Siavoshi (triple board-certified in Neurology, Headache Medicine, and Obesity Medicine) offering compounded semaglutide and tirzepatide injections through USP-certified 503B pharmacies.
Longevixx sells lab-informed dosing and cadenced check-ins, publishes no lab price and no lab requirement, and prints “same price, no hidden fees” above a card that rises after month one.
NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound.
TRYM Health (TRYM) is a nationwide telehealth service offering compounded GLP-1 weight-loss medication — semaglutide (~$96/mo, $3.20/day) and tirzepatide (~$126/mo, $4.20/day) — as additive-free multi-dose vials covering all doses, with a starter kit, temperature-controlled shipping, FSA/HSA eligibility, and flexible cancellation.
The 21 rankings nearest this one
- #119 AlyveRx70.5
- #120 The Edit70.4
- #121 eMI Aesthetics70.3
- #122 RedBox Rx70.2
- #123 Rex MD70.2
- #124 Kina70.1
- #125 OnlineSemaglutide.org70.1
- #126 YOURx Health70
- #127 Remote Pharmacy69.9
- #128 Alternate Health Club69.8
- #129 Navio MD69.8
- #130 Bon Health69.7
- #131 Heva Health69.7
- #132 Livea69.7
- #133 Nolu69.7
- #134 GoodRx69.6
- #135 Jyra Health69.6
- #136 Medi-Weightloss69.6
- #137 YourHealthRx69.6
- #138 FeelGood69.5
- #139 Cielo69.4
Pricing/verification reflect Edessa's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Edessa's site. Not medical advice; see our disclosure.